Dxd is primarily utilized in the development of antibody-drug conjugates (ADCs), which are a class of targeted cancer therapies. It serves as a potent cytotoxic payload that is attached to monoclonal antibodies, enabling the precise delivery of the drug to cancer cells while minimizing damage to healthy tissues. This targeted approach enhances the efficacy of cancer treatment and reduces systemic toxicity. Dxd's high potency makes it particularly effective in treating various types of cancers, including breast, gastric, and lung cancers, where it has shown promising results in clinical trials. Its application in ADCs represents a significant advancement in the field of oncology, offering new hope for patients with difficult-to-treat malignancies.